Pfizer remains quiet for its next marketing ploys because it is enjoying high ratings in the third quarter. Their quality cancer drug is still the reason behind the good performance and output that they have got.
There are issues before that they will be acquiring AstraZeneca PLC but this still remains a plan for the company. They will have to work with the increase demand for their medicines in the growing market.
They actually made a bidding in early 2014, May 26 exactly to acquire AstraZeneca PLC. However, their bid of $118 billion was not accepted by the latter. There is still a chance for the company to post their bid come December. However, they do not release any numbers or any plans to pursue with the plans yet.
The score was at 57 cents per share. This is already impressive knowing that their special products are not yet counted in the total tally. Analysts fell 2 cents short when they predicted the performance of the largest medicine company.
This could be a move from the company to increase its portfolio as they are expecting downfall in the coming years. This is because certain patents under their brand are about to expire.